KAPA
Kairos Pharma, Ltd.AMEX
Healthcare • Biotechnology
$0.49+7.33%
Close Nov 6, 2026
- Market cap
- $1.49M
- 1 month
- -49.2%
- 3 months
- -80.1%
- 1 year
- -92.6%
- Dividend
- No dividends on record
- Short interest
- 6.0% of float134.5K shares · settled Oct 15, 2026 · +18.9% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$5.81M
- Free cash flow
- -$3.97M
- Book value
- $4.19M
- Total debt
- —
- P/E
- —
- Price / sales
- —
- Price / book
- 0.4×
- FCF yield
- -265.9%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Read more
It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
- Website
- kairospharma.com
- Headquarters
- Los Angeles, CA, United States
- Employees
- 1
- Listed
- Sep 16, 2024
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 28, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 12, 2026 | — | — | — | -$1.4M | -$1.4M |
| Mar 2026filed May 13, 2026 | — | — | — | -$1.6M | -$1.7M |
| Dec 2025filed Mar 31, 2026 | — | — | — | -$1.6M | -$1.4M |
| Sep 2025filed Nov 14, 2025 | — | — | — | -$1.4M | -$1.4M |
| Jun 2025filed Aug 12, 2025 | — | — | — | -$1.5M | -$1.4M |
| Mar 2025filed May 14, 2025 | — | — | — | -$1.3M | -$1.3M |
| Dec 2024 | — | — | — | -$1.4M | -$980.0K |
| Sep 2024filed Nov 14, 2024 | — | — | — | -$383.0K | -$1.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 31, 2026 | — | — | — | -$5.6M | -$5.4M |
| Dec 2024filed Apr 15, 2025 | — | — | — | -$2.3M | -$2.6M |
| Dec 2023filed Dec 31, 2023 | — | — | — | -$1.7M | -$1.8M |
| Dec 2022filed Dec 31, 2022 | — | — | — | -$571.0K | -$1.1M |
| Dec 2021filed Dec 31, 2021 | — | — | — | -$1.9M | -$2.1M |
| Dec 2020filed Dec 31, 2020 | — | — | — | -$1.0M | -$1.1M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched KAPA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
134,519 shares short
+21,338 shares (+18.9%) vs Sep 30, 2026
6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
113,181 shares short
-1,207 shares (-1.1%) vs Sep 15, 2026
5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
114,388 shares short
A split falls between these reports; the share-count change is not compared.
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
403,209 shares short
+38,961 shares (+10.7%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
364,248 shares short
-153,572 shares (-29.7%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
517,820 shares short
+325,647 shares (+169.5%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind KAPA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 7 · reverse split
Effective Sep 1, 2026
Each 7 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if KAPA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
2 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 10
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
14 filers reported a long position in KAPA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
97.4%
of the 968K shares 13-F filers reported
Moves vs Q1 2026
0 added1 trimmed
4 new · 5 unchanged
Net shares held
-6.2%
across the 6 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $118.9K · 309.8K shares | 309.8K | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $89K · 231.9K shares | 231.9K | Unchanged |
| 3 | Virtu Financial LLC | $31K · 82.1K shares | 82.1K | New |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $30.3K · 78.9K shares | 78.9K | -29.1% |
| 5 | VANGUARD FIDUCIARY TRUST CO | $24.5K · 63.9K shares | 63.9K | Unchanged |
| 6 | SevenBridge Financial Group, LLC | $17.1K · 44.3K shares | 44.3K | Unchanged |
| 7 | Aptus Capital Advisors, LLC | $17K · 44.3K shares | 44.3K | Unchanged |
| 8 | JANE STREET GROUP, LLC | $12.9K · 33.7K shares | 33.7K | New |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.2K · 29.3K shares | 29.3K | New |
| 10 | STATE STREET CORP | $9.2K · 24.1K shares | 24.1K | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for KAPA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.